Primary endpoint was not met for the modified intent-to-treat (mITT) population; however, clinical benefit observed in coronary artery bypass graft (CABG) patients
Data showed relative risk reduction in specific study populations and overall lower rates of rehospitalization within 30 days compared to placebo
Adverse Events (AEs) were numerically similar across treatment groups
Results were presented today as part of a late-breaking science session at the 2022 American Heart Association Scientific Sessions
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.